Compare Enveric Biosciences Inc (ENVB) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Target Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Target Corporation trades at $154.65 (market cap $70.31B). The key difference: Target Corporation is far larger — about 10339.7× Enveric Biosciences Inc's market cap, and Target Corporation pays a 3% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Target Corporation for 137 Days on average.
| ENVB | TGT | |
|---|---|---|
Market Cap | $6.80M | $70.31B |
Volume | 64,867 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $169.90 |
52-Week Low | $1.27 | $83.68 |
Typical Hold Time | 14 Days | 137 Days |
Enterprise Value | -$1.49M | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Target trades at $150.96, down 2.18% today, with technical indicators showing bearish momentum. The company maintains solid fundamentals with a P/E of 16.05 and strong profitability metrics including 26.41% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 forecast. The company's holiday price-cutting strategy aims to capture market share amid competitive retail pressures.
Target presents a mixed outlook with 46.7% analyst buy ratings and a $167.18 consensus target suggesting 10.8% upside. Strong cash flow generation and dividend sustainability support the investment case, though margin pressures from aggressive pricing and retail competition pose near-term challenges. The stock's current valuation appears reasonable relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
